Management of i therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements

Nuclear Medicine Communications

Volumn 26, Issue 7, 2005, Pages 623-631

  Pacilio, Massimiliano ^a   Bianciardi, Luciano ^b   Panichelli, Vincenzo ^a   Argirò, Giovanni ^a   Cipriani, Cesidio ^a  

^a S EUGENIO HOSPITAL   (Italy)

^b SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

Author keywords

Nursing staff; Patient discharge; Radiometry; Total body clearance

Indexed keywords

RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; IODINE 131;

ARTICLE; BODY BURDEN; CLINICAL TRIAL; HALF LIFE TIME; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; ITALY; METABOLIC CLEARANCE RATE; METABOLISM; PERSONNEL MANAGEMENT; RADIATION DOSE; RELATIVE BIOLOGIC EFFECTIVENESS; STATISTICS; THYROID TUMOR; DOSIMETRY; DRUG HALF LIFE; HEMODIALYSIS; HOSPITALIZATION; MAJOR CLINICAL STUDY; NURSING STAFF; RADIOISOTOPE THERAPY; RADIOMETRY; STATISTICAL ANALYSIS; STATISTICAL MODEL; THYROID CANCER; THYROIDECTOMY;

BODY BURDEN; HALF-LIFE; HUMANS; INPATIENTS; IODINE RADIOISOTOPES; ITALY; METABOLIC CLEARANCE RATE; PATIENT DISCHARGE; PERSONNEL STAFFING AND SCHEDULING; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RELATIVE BIOLOGICAL EFFECTIVENESS; THYROID NEOPLASMS;

EID: 21344472362     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000167909.69095.c9     Document Type: Article

References (20)

1. Bushnell DL, Boles MA, Kaufman GE, Wadas MA, Barnes WE. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl Med 1992; 33:2214-2221.
2. European Commission. Radiological Protection 97. Radiation Protection Following Iodine-131 Therapy (Exposures due to Out-patients or Discharged In-patients). Brussels: Directorate-General Environment, Nuclear Safety and Civil Protection; 1998.
3. Siegel JA, Marcus CS, Sparks RB. Calculating the absorbed dose from radioactive patients: the line-source versus point-source model. J Nucl Med 2002; 43:1241-1244.
4. Armitage P. Statistical Methods in Medical Research. New York: Blackwell Scientific Publications; 1971.
5. Crow EL, Shimizu K. Lognormal Distribution: Theory and Applications. New York: Marcel Dekker; 1988.
6. Barrington SF, Kettle AG, O'Doherty MJ, Wells CP, Somer EJR, Coakley AJ. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med 1996; 23:123-130.
7. Mountford PJ. Estimation of close contact doses to young infants from surface dose rates on radioactive adults. Nucl Med Commun 1987; 8:857-863.
8. Mountford PJ. Risk assessment of the nuclear medicine patient. Br J Radiol 1997; 70:671-684.
9. 131I therapy patient. J Nucl Med Technol 2001; 29:61-66.
10. Daumerie C, Vynckier S, Caussin J, Jadoul M, Squifflet JP, de Patoul N, et al. Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis. Thyroid 1996; 6:301-304.
11. 131I therapy for thyroid carcinoma in a patient with severely impaired renal function on chronic dialysis: a case report. Jpn J Clin Oncol 2002; 32:202-205.
12. Mello AM, Isaacs R, Petersen J, Kronenberger S, McDougall IR. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis. Clin Nucl Med 1994; 19:776-781.
13. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002; 12:121-134.
14. Beierwaltes WH. Radioiodine therapy of thyroid disease. Nucl Med Biol 1987; 14:177-181.
15. 131I outpatient therapy. J Nucl Med Technol 2002; 30:165-171.
16. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun 2003; 24:489-495.
17. Hoyes KP, Owens SE, Millns MM, Allan E. Differentiated thyroid cancer: radioiodine following lobectomy - a clinical feasibility study. Nucl Med Commun 2004; 25:245-251.
18. Arslan N, Ilgan S, Serdengecti M, Ozguven MA, Bayhan H, Okuyucu K, et al. Post-surgical ablation of thyroid remnants with high-dose (131)I in patients with differentiated thyroid carcinoma. Nucl Med Commun 2001; 22:1021-1027.
19. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9:421-427.
20. Allan E, Owens SE, Waller ML. Differentiated thyroid cancer: lobectomy and radioiodine, a treatment suitable for all cases? Nucl Med Commun 1999; 20:983-989.